Circulating MicroRNAs: Biogenesis and Clinical Significance in Acute Myocardial Infarction

Lei Zhang,Han Ding,Yuan Zhang,Yin Wang,Wenjie Zhu,Peifeng Li

DOI: https://doi.org/10.3389/fphys.2020.01088

IF: 4

2020-09-03

Frontiers in Physiology

Abstract:Acute myocardial infarction (AMI) causes many deaths around the world. Early diagnosis can prevent the development of AMI and provide theoretical support for the subsequent treatment. miRNAs participate in the AMI pathological processes. We aim to determine the early diagnostic and the prognostic roles of circulating miRNAs in AMI in the existing studies and summarize all the data to provide a greater understanding of their utility for clinical application. We reviewed current knowledge focused on the AMI development and circulating miRNA formation. Meanwhile, we collected and analyzed the potential roles of circulating miRNAs in AMI diagnosis, prognosis and therapeutic strategies. Additionally, we elaborated on the challenges and clinical perspectives of the application of circulating miRNAs in AMI diagnosis. Circulating miRNAs are stable in the circulation and have earlier increases of circulating levels than diagnostic golden criteria. In addition, they are tissue and disease-specific. All these characteristics indicate that circulating miRNAs are promising biomarkers for the early diagnosis of AMI. Although there are several limitations to be resolved before clinical use, the application of circulating miRNAs shows great potential in the early diagnosis and the prognosis of AMI.

physiology

What problem does this paper attempt to address?

This paper attempts to solve the problem of early diagnosis of acute myocardial infarction (AMI). AMI is a serious cardiovascular disease, and early diagnosis is crucial for controlling its development and conducting appropriate treatment to reduce mortality. Currently, commonly used AMI diagnostic markers in clinical practice, such as troponin (TnI/TnT), CK - MB and myoglobin, etc., although non - invasive and can be continuously sampled in real - time, they do not start to increase until at least 3.5 hours after the onset of AMI, so they are not effective for the early diagnosis of AMI. In addition, the diagnostic value of these protein markers may be affected by factors such as the patient's genetic background, age, lifestyle, and medication.

The paper points out that microRNAs (miRNAs) have multiple biological and pathological functions and are tissue - or cell - specific. miRNAs have also been found to exist in the circulatory system, which opens up new possibilities for circulating miRNAs as potential biomarkers for the diagnosis of cardiovascular diseases. Therefore, this article aims to summarize the existing knowledge and findings regarding circulating miRNAs in the diagnosis of AMI, with particular attention to their advantages, and to explore the potential clinical applications of circulating miRNAs as biomarkers for the early diagnosis of AMI.

Specifically, the paper discusses the generation mechanism of circulating miRNAs, their role in the diagnosis of AMI, and the challenges they face. Circulating miRNAs are considered ideal candidates for the early diagnosis of AMI because of their high stability, tissue and disease specificity, and early elevation characteristics. The paper also lists the research results of multiple heart - and muscle - enriched miRNAs (such as miR - 1, miR - 133, miR - 208 and miR - 499) that are significantly increased in AMI patients, further supporting the potential of circulating miRNAs in the diagnosis of AMI. Although there are some limitations that need to be addressed, circulating miRNAs show great potential in the early diagnosis and prognostic evaluation of AMI.